SecBot SecBot
8-K ·Filed Nov 5, 2026

PYXS

Pyxis Oncology, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 19h ago SEC0001193125-26-448604
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The Phase 3 Headliner trial design alignment with FDA/EMA is the key catalyst path; watch for FDA dose selection feedback in Q1 2027 and the December 2026 corporate update with combination data. The $110M offering extends runway but adds dilution (shares outstanding rose from ~83M to ~120M).

DirectionNeutral
Confidencehigh
Horizonmonths

PYX-201

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1 / Phase 1/2
Time to market
At least 2-3 years, assuming Phase 3 trial (planned mid-2027) succeeds and leads to an NDA filing. No regulatory filing has occurred yet.
Next catalyst
None dated

What to watchThe next near-term catalyst is the EORTC-NCI-AACR late-breaking oral presentation (Nov 18-20, 2026), though the top-line data has already been disclosed. The true binary events are: Q4 2026 updated combo data, Q1 2027 End-of-Phase 2 meeting with FDA, and H1 2027 overall survival data from the monotherapy study, any of which could drive major moves. The $3.50 common warrant exercise trigger (requiring both shareholder approval and OS data) creates an additional overhang that could cap upside until clarity emerges.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.61
T+0 close · Nov 5, 2026 · via day close
Latest settled
−1.86%
T+5 · $1.58
Vs SPY
−5.15%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $1.61entry
  2. T+1 · 11d ago +3.11%α +2.79% · $1.66
  3. T+5 · 5d ago −1.86%α −5.15% · $1.58
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pyxis Oncology reported Q3 2026 net loss of $20.0M ($0.24 per share), narrower than the $22.0M loss in Q3 2025, driven by lower R&D and G&A expenses. The company highlighted progress toward pivotal development of its lead ADC candidate MICVO, including alignment with FDA and EMA on Phase 3 trial design, a $110M public offering extending cash runway into H1 2028, and updated Phase 1 monotherapy data showing a 36% confirmed ORR in 2L+ R/M HNSCC. No consensus EPS was provided for this quarter, so no beat/miss verdict is assigned.

Key Financial Metrics

EPS
−$0.24
Revenue
$0.00
est $0.00

Key Facts

  • Q3 2026 net loss of $20.0M ($0.24/share) vs $22.0M ($0.35/share) in Q3 2025
  • Cash, equivalents, and short-term investments of $57.0M at Sept 30, 2026; after $110M public offering, cash runway into H1 2028
  • FDA and EMA alignment on global Phase 3 Headliner trial design for MICVO in 2L+ R/M HNSCC; trial initiation planned for mid-2027
  • Updated Phase 1 monotherapy data: 36% confirmed ORR (12/33), 94% DCR, median PFS 6.2 months, 12-month OS probability 79%
  • October 2026 public offering generated ~$110M upfront gross proceeds; milestone-linked warrants could add ~$172.6M if exercised
  • Tom Civik appointed CEO and Chairman in September 2026
  • Outstanding shares as of Nov 4, 2026: 119,607,855

Financial Impact

Q3 net loss $20.0M; cash position $57.0M pre-offering; $110M public offering closed Oct 1, 2026

cash runwaydilutionnet loss

Risk Factors

  • Clinical-stage biotech with no approved products or revenue; depends on successful Phase 3 outcomes
  • Significant dilution from October 2026 public offering and outstanding warrants
  • Competitive landscape in R/M HNSCC includes established therapies and other ADCs

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-448604
Document: pyxs-20261105.htm0001193125-26-448604
Document: 0001193125-26-448604-index-headers.html0001193125-26-448604
Document: 0001193125-26-448604-index.html0001193125-26-448604
Document: 0001193125-26-448604.txt0001193125-26-448604
8-K Data (Synthetic)0001193125-26-448604

Track record

25 reports on PYXS

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
  3. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $1.61 Now $1.41 −12.42% settles Dec 4
  5. Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
  6. Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
  7. Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
  8. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
  9. Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
  10. Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026